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Obesity has become a major health problem. Testosterone plays a signiﬁcant role in obesity, glucose homeostasis, and lipid
metabolism. The metabolic syndrome is a clustering of risk factors predisposing to diabetes mellitus type 2, atherosclerosis, and
cardiovascular morbidity and mortality. The main components of the syndrome are visceral obesity, insulin resistance, glucose
intolerance, raised blood pressure and dyslipidemia (elevated triglycerides, low levels of high-density lipoprotein cholesterol), and
a proinﬂammatory and thrombogenic state. Cross-sectional epidemiological studies have reported a direct correlation between
plasma testosterone and insulin sensitivity, and low testosterone levels are associated with an increased risk of type 2 diabetes
mellitus, dramatically illustrated by androgen deprivation in men with prostate carcinoma. Lower total testosterone and sex
hormone-binding globulin (SHBG) predict a higher incidence of the metabolic syndrome. Administration of testosterone to
hypogonadal men reverses part of the unfavorable risk proﬁle for the development of diabetes and atherosclerosis.
1.Introduction
A major problem is the management of overweight. Obesity
is a condition that is reaching epidemic proportions in both
thedevelopedandthedevelopingworld.IntheUnitedStates,
63% of men and 55% of women are classiﬁed as overweight.
Of these, 22% are deemed grossly overweight, with a body
mass index above 30kg/m2, and the consequences of this
rapid increase are serious [1]. Approximately 80% of obese
adults suﬀer from at least one, and 40% from two or
more of the diseases associated with obesity, such as type
2 diabetes, hypertension, cardiovascular disease, gallbladder
disease, cancers, and diseases of the locomotor system, such
as arthrosis [2].
Thiscontributionwillhighlightthesigniﬁcanceoftestos-
terone in the development and treatment of obesity. The
reality of life is that the practice of medicine is subdivided
into medical specialties, each with its own perspective
and problems. Obesity and particularly its sequels, such
as diabetes mellitus, cardiovascular disease, and locomotor
problems, are not primarily treated by endocrinologists.
Evenamongendocrinologiststheexpertiseonsexhormones,
not to speak of testosterone, is often limited. This contribu-
tion will argue that testosterone has a signiﬁcant role to play
in the etiology and treatment of obesity and its sequels in the
male.
2. Sex Differences in Fat Distribution
Adult men and women diﬀer in their fat distribution;
the regional distribution of body fat is a characteristic of
masculinity and femininity [3]. In premenopausal women
a larger proportion of fat is stored in peripheral fat depots
such as breasts, hips, and thighs. Men tend to deposit
excess fat in the abdominal regions (both subcutaneous and
intra-abdominal or visceral fat depots) and generally have
a larger visceral fat depot than (premenopausal) women
[4]. As regional localization of body fat is considered a
secondary sex characteristic, it is likely that sex steroids are
involved in the male and female patterns of fat deposition.2 Journal of Obesity
This view is strengthened by the observation that variations
in sex steroid levels in diﬀerent phases of (reproductive)
life parallel regional diﬀerences in fat storage and fat
mobilization, until puberty boys and girls do not diﬀer
very much in the amount of body fat and its regional
distribution. From puberty on words, diﬀerences become
manifest [5, 6]. The ovarian production of estrogens and
progesterone induce an increase in total body fat as well
as selective fat deposition in the breast and gluteofemoral
region. Pubertal boys show a strong increase in fat free
mass while the amount of total body fat does not change
very much [5]. Adolescent boys lose subcutaneous fat but
accumulate fat in the abdominal region, which in most
boys, is not very visible in that stage of development but
clearly demonstrable with imaging techniques [7]. The sex
steroid-induced regional distribution is not an all-or-none
mechanism; it is a preferential accumulation of excess fat.
Obese men and women still show their sex-speciﬁc fat
accumulation but store their fat also in the “fat depots of
the other sex”. Not only the fat distribution diﬀers between
the sexes from puberty on, but also the dynamics of fat
cell size and fat metabolism are diﬀerent. The amount of
fat in a certain depot is dependent on the number and size
of the fat cells. Fat cells in the gluteal and femoral region
are larger than in the abdominal region [8]. The activity of
lipoprotein lipase, the enzyme responsible for accumulation
of triglycerides in the fat cell, is higher in the gluteo-femoral
region than in the abdominal area [9]. Conversely, lipolysis
is regulated by hormone sensitive lipase, which in turn
is regulated by several hormones and by the sympathetic
nervoussystem.Catecholaminesstimulatelipolysisviatheβ-
adrenergic receptor while α2-adrenoreceptors inhibit lipol-
ysis. Hormones aﬀect the catecholamine receptors of the
adipocytes.Testosteronestimulatestheβ-adrenergicreceptor
while estrogens/progesterone stimulate preferentially α2-
adrenoreceptors [10]. Insulin stimulates fat accumulation.
It is not an unreasonable speculation that the sex steroid-
dependent fat distribution serves (or from this millennium
on has served?) the diﬀerent roles of men and women in
reproduction and caring for their progeny. The visceral fat
depot constitutes a quickly available source of calories and
energy. By its close anatomical proximity to the liver, it
delivers fatty acids through the portal system [11]. The latter
may have served a useful function in evolution when there
was a more pronounced labour division between the sexes
suiting the needs of men in their manual labour and quick
physical action.
3. The Paradoxical Relationshipsof
Testosterone and Fat Distributionin
Adulthood and Ageing
While the evidence that pubertal sex steroids induce a sex-
speciﬁc fat distribution with preferential abdominal/visceral
fataccumulationinmalesandpreferentialgluteo-femoralfat
accumulation in females is quite solid, later in life a number
of paradoxes occur in the relationship between sex steroids
and fat distribution.
Acquired adult onset hypogonadism in men is associated
with an amount of visceral fat which is not less and mostly
morethaninacomparisongroupofeugonadalmen[12].So,
apparentlywhileandrogensinducevisceralfataccumulation,
once fat has been stored in the visceral depot it does not need
continued androgen stimulation as opposed to maintenance
of bone and muscle mass, which are lower in men with
adult onset hypogonadism than in eugonadal controls [13].
Induction of androgen deﬁciency by administration of an
LHRHagonistleadstoanincreaseoffatmass[14].Androgen
deprivation treatment of men with prostate cancer increases
fatmass,reducesinsulinsensitivity,andimpairslipidproﬁles
increasing cardiovascular risk [15, 16] or worsens metabolic
control of men with diabetes mellitus considerably [17].
Correlation studies in large groups of subjects have shown
that visceral fat increases with ageing. There is an inverse
correlation between the amount of visceral fat and plasma
insulin on the one hand and levels of testosterone and SHBG
on the other [18, 19]. Correlation studies cannot unravel
the cause and eﬀect relationships between the correlates
whether low testosterone induces visceral fat deposition or
whether a large visceral fat depot leads to low testosterone
levels.Prospectivestudieshaveconﬁrmedthatlowerendoge-
nous androgens predict central adiposity in men [20]a n d
that these low testosterone levels are signiﬁcantly inversely
associated with levels of blood pressure, fasting plasma
glucose, triglycerides, and body mass index but positively
correlated with HDL-cholesterol [21]. A ﬁve-year follow-
up study of Swedish men indicated that elevated plasma
cortisol and low testosterone were prospectively associated
with increased incidence of cardiovascular-related events
and diabetes mellitus type 2 [20]. The fact that androgen
deprivation of men with prostate cancer induces a worsening
of elements of the metabolic syndrome reveals a role for
testosterone in its etiology [15, 22].
4.The MetabolicSyndrome
A closer examination of obesity has revealed that a
preferential accumulation of fat in the abdominal region is
associated with an increased risk of noninsulin-dependent
diabetes mellitus and cardiovascular disease, not only in
obese subjects but even in non-obese subjects [23]. A
large number of cross-sectional studies have established a
relationship between abdominal obesity and cardiovascular
risk factors such as hypertension, dyslipidaemia (elevated
levels of cholesterol, of triglycerides, of low-density
lipoproteins and low levels of high-density lipoproteins),
impaired glucose tolerance with hyperinsulinaemia, a cluster
known as the “insulin resistance syndrome” or “metabolic
syndrome” [24–27]. The term metabolic syndrome is
now preferred. There is a debate in the literature whether
combining these components or conditions has an added
diagnostic or prognostic value [28]. In recent years, three
main deﬁnitions of the metabolic syndrome were used.
These deﬁnitions overlapped but diﬀer in the points of
emphasis of the components. The deﬁnition of the National
Cholesterol Education program places equal emphasis
on the various components of the metabolic syndromeJournal of Obesity 3
[29]. The deﬁnition adopted by the WHO assigns greater
value to insulin resistance as a required component of the
metabolic derangements [30]. Increasingly, professional
organizations have now proposed deﬁnitions. The
International Diabetes Federation has drafted a singly
unifying deﬁnition in 2005. The main emphasis in this
deﬁnition is central obesity deﬁned by waist circumference:
waist circumference in Europids ≥94cm and in Asians
>90cm and two or more of the following four factors:
elevated triglycerides ≥1.7mmol/L (≥150mg/dL), reduced
HDL-cholesterol<1.03mmol/L(<40mg/dL),elevatedblood
pressure systolic ≥130mmHg, diastolic ≥85mmHg (or
treatment), and dysglycaemia (raised fasting plasma glucose
≥5.6mmol/L (≥100mg/dL) (or type 2 diabetes) [31],
(http://www.idf.org/webdata/docs/MetSyndrome FINAL
.pdf). Recently, several scientiﬁc societies have arrived at a
joint interim statement to harmonize the approach to the
metabolic syndrome [32].
5. Testosterone in Men Sufferingfrom the
MetabolicSyndrome andDiabetesMellitus
Numerous studies have found inverse associations between
the severity of features of the metabolic syndrome and
plasma testosterone [33–38]. For review see [39]. There is an
inverse relationship between waist circumference, a reliable
indicator of visceral obesity, and testosterone levels over all
age groups [40].
The inverse relationship of testosterone and the
metabolic syndrome is consistent across race and ethnic
groups [41]. Similar to studies in men with the metabolic
syndrome, there is in men an inverse relationship between
testosterone levels and diabetes. For review: [42]. Men with
diabetes have lower testosterone levels compared to men
without a history of diabetes [43, 44], and there is an inverse
association between testosterone levels and glycosylated
hemoglobin [45]. This is no artifact due to medication
with, for instance, statins [44]. A systematic review and
meta-analysis of cross-sectional studies indicated that
testosterone level was signiﬁcantly lower in men with type
2 diabetes (mean diﬀerence, −76.6ng/dL; 95% conﬁdence
interval [CI], −99.4 to −53.6) [46]. In men with low
plasma testosterone, the likelihood of diabetes mellitus is
increased. Prospective studies have shown that men with
higher testosterone levels (range 449.6–605.2ng/dL) had a
42% lower risk of type 2 diabetes (RR, 0.58; 95% CI, 0.39 to
0.87) [46]. In addition, several large prospective studies have
shown that low testosterone levels predict development of
type 2 diabetes in men. There is persuasive epidemiological
evidence form several longitudinal population studies
that low testosterone is an independent risk factor for the
development of both the metabolic syndrome and type 2
diabetes in later life [43, 47] and their clinical sequels such as
stroke or transient ischemic attacks [48]. The Massachusetts
Male Aging Study (MMAS) [49] and the Multiple Risk
Factor Intervention Trial (MRFIT) [50] have shown that low
levels of total testosterone and SHBG (which is associated
with insulin resistance) were both independent risk factors
in middle-aged men who later developed diabetes. The
Rancho-Bernardo Study based in California demonstrated
a signiﬁcant inverse correlation between baseline total
testosterone with long-term (8-year follow-up) fasting
glucose and insulin levels as well as glucose intolerance
[51]. A Finnish study has shown that low testosterone and
SHBG levels also predict the development of the metabolic
syndrome as well as diabetes [18], recently conﬁrmed by a
German group [52]. Importantly, the MMAS has provided
evidence that low testosterone is a risk factor for metabolic
syndrome and diabetes in men who were not initially obese
[19]. Recently the Third National Health and Nutrition
survey (NHANES III) in a population of 1,413 men after
adjustment for age, race/ethnicity, and adiposity showed
that those men initially in the lowest tertile of either free or
bioavailable (but not total testosterone) were approximately
four times more likely to have prevalent diabetes compared
tothoseinthethirdtertile[53].Theseﬁndingssupportthose
of the MMAS in that the risk is independent of adiposity
[49]r e c e n t l yc o n ﬁ r m e di nA u s t r a l i a[ 54]. For review see
[47, 55].
Interestingly, there is a signiﬁcant diﬀerence in plasma
testosterone levels between men with diabetes type 1 (who
have normal levels) and type 2 (who have subnormal levels)
[56]. This diﬀerence was attributed to the diﬀerences in
circulating levels of insulin (low in type 1 and high in type
2).Thereisaninverserelationshipbetweeninsulinlevelsand
sex hormone-binding globulin (SHBG) and, consequently,
plasma levels of total testosterone are lower in men with type
2 diabetes. This assumption is conﬁrmed by the observation
that men with type 1 diabetes with a high BMI show
lower levels of testosterone. Androgen receptor CAG repeat
polymorphism appears associated with serum testosterone
levels, obesity, and serum leptin in men with type 2 diabetes
[57].
6. The Vicious Circleof Low Testosterone and
the MetabolicSyndrome
Adiposity with its associated hyperinsulinism suppresses sex
hormone-binding globulin (SHBG) synthesis and therewith
the levels of circulating testosterone [58, 59]. It also may
aﬀect the strength of luteinizing hormone (LH) signaling to
the testis [60]. Further, insulin [61] and leptin [62]h a v ea
suppressive eﬀect on testicular steroidogenesis [45]. So, there
are reasons to believe that adiposity is a signiﬁcant factor in
lowering circulating levels of testosterone, even occurring in
men under the age of 40 years [63]. For review see [64, 65].
While it is clear that disease, and in the context of
this contribution, in particular the metabolic syndrome
suppresses circulating testosterone levels, it has also been
documented that low testosterone induces the metabolic
syndrome [18, 49]. Even in the absence of late-stage conse-
quences such as diabetes and cardiovascular disease, subtle
derangements in sex hormones are present in the metabolic
syndrome and may contribute to its pathogenesis [66].
The role of testosterone is dramatically demonstrated
by ﬁndings in men with prostate cancer who undergo4 Journal of Obesity
androgen ablation therapy [22, 67], particularly in the
longer-term [68]. Another study showed convincingly that
acute androgen deprivation reduces insulin sensitivity in
young men [69] and strongly impairs glycemic control of
men with diabetes mellitus [70].
7. Can the Age-Related Declineof
Testosterone Be Prevented or Reversed?
As indicated above the age-related changes in neuroen-
docrine functioning leading to a diminished eﬃcacy of
LH stimulation of the Leydig cell and impairments of the
steroidogenic process of testosterone synthesis are probably
inherent factors in the age-related decline of circulat-
ing testosterone levels [58, 71]. But increasingly there is
insight that disease signiﬁcantly contributes to the age-
related decline of testosterone [72]. Changes in lifestyle
(diet/exercise) might partially prevent or redress the decline
of androgen levels with aging [73–75] and should be
encouraged.
8. Effects of Testosterone Administration on
FatTissueandLipidMetabolism
Sex steroid hormones are involved in the metabolism,
accumulation, and distribution of adipose tissues. It is now
known that estrogen receptors, progesterone receptors, and
androgen receptors exist in adipose tissues, so their actions
could be direct. Sex steroid hormones carry out their func-
tion in adipose tissues by both genomic and nongenomic
mechanisms. Activation of the cAMP cascade by sex steroid
hormones would activate hormone-sensitive lipase leading
to lipolysis in adipose tissues. In the phosphoinositide
cascade, diacylglycerol and inositol 1,4,5-trisphosphate are
formed as second messengers ultimately causing the acti-
vation of protein kinase C [76]. Their activation appears
to be involved in the control of preadipocyte proliferation
and diﬀerentiation. The role of testosterone in regulating
lineage determination in mesenchymal pluripotent cells by
promoting their commitment to the myogenic lineage and
inhibiting their diﬀerentiation into the adipogenic lineage
through an androgen receptor-mediated pathway has been
convincingly demonstrated [77]. In a clinical study, it could
be shown that testosterone inhibits triglyceride uptake and
lipoprotein lipase activity and causes a more rapid turnover
of triglycerides in the subcutaneous abdominal adipose
tissue and less so in femoral fat and, maybe, mobilizes
lipids from the visceral fat depot. In this study, testosterone
administration restoring testosterone levels to midnormal
values with a duration of 8-9 months led to a decrease of
the visceral fat mass, a decrease of fasting glucose and lipid
levels and an improvement of insulin sensitivity; in addition,
a decrease in diastolic blood pressure was observed [76].
A meta-analysis of randomized controlled trials eval-
uating the eﬀects of testosterone (T) administration to
middle-aged and ageing men on body composition showed
a reduction of 1.6kg (CI: 2.5–0.6) of total body fat,
corresponding to −6.2% (CI: 9.2–3.3) variation of initial
body fat, an increase in fat-free mass of 1.6 kg (CI: 0.6–2.6),
corresponding to +2.7% (CI: 1.1–4.4) increase over baseline
and no change in body weight. In a placebo-controlled
study using long-acting testosterone indecanoate injections,
the reduction of fat mass was 5.3kg with an increase of
lean mass of 4.2kg [78]. Testosterone also reduced total
c h o l e s t e r o lb y0 . 2 3m m o l / L( C I :−0.37 to −0.10), especially
in men with lower baseline T concentrations, with no change
in low density lipoprotein (LDL-) cholesterol. A signiﬁcant
reductionofhighdensitylipoprotein(HDL-)cholesterolwas
found only in studies with higher mean T-values at baseline
or when androgens were nonaromatizable (−0.085mmol/l,
CI: −0.017 to −0.003) [79]. This underlines the necessity to
use the chemically unmodiﬁed molecule of testosterone for
treatment.
9. Testosterone Administration to Men with the
MetabolicSyndrome andDiabetesMellitus
So, it is clear now that low testosterone levels are a factor
in the etiology of common ailments of elderly men such as
the metabolic syndrome and its associated diseases such as
diabetes mellitus and atherosclerotic disease. The question
arises then whether testosterone treatment has a role to play
in the treatment of the metabolic syndrome and its sequels
such as diabetes mellitus type 2 and cardiovascular disease.
There is increasing evidence of a beneﬁcial eﬀect of testos-
terone treatment on visceral fat and other elements of the
metabolic syndrome [80]. Changes in visceral fat appeared
to be a function of changes in serum total testosterone [81].
Thebeneﬁcialeﬀectsofandrogenson(visceral)fathavebeen
conﬁrmed in other studies [82, 83]. A study investigating the
eﬀects of normalization of circulating testosterone levels in
men with subnormal testosterone levels receiving treatment
with parenteral testosterone undecanoate found favorable
eﬀects on body composition (waist circumference) [84].
In another study, 32 hypogonadal (plasma testosterone
<12nmol/L) men with the metabolic syndrome, with newly
diagnosed type 2 diabetes mellitus were single-blindly ran-
domized to diet and exercise alone (n = 16) or to diet and
exercise in combination with testosterone gel 50mg once
daily (n = 16) and treated for 52 weeks. No glucose-lowering
agentswereadministeredpriortoorduringthestudyperiod.
Addition of testosterone signiﬁcantly further improved these
measures compared to diet and exercise alone on glycaemic
control, waist circumference, and other parameters of the
metabolic syndrome [75].
Testosterone substitution in hypogonadal men improves
insulin sensitivity [85]. Furthermore, testosterone reduces
insulin levels and insulin resistance in men with obesity. A
study in hypogonadal men with type 2 diabetes has shown
that testosterone replacement also improves glycaemic con-
trol although this study was nonblinded [86]. In a recent
Korean study, glucose levels were signiﬁcantly reduced after
24 weeks of testosterone treatment in men with baseline
glucose ≥110mg/dL while there was no change in men
with baseline glucose <110mg/dL [87]. By contrast, two
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and hypogonadism found little or no eﬀect on glycaemic
control [88,89],butamorerecentstudyanalyzingtheeﬀects
of testosterone administration to 24 hypogonadal men (10
treated with insulin) over the age of 30 years with type 2 dia-
betes found that testosterone replacement therapy reduced
insulin resistance (as measured by homeostatic model index)
and improved glycaemic control in hypogonadal men with
type 2 diabetes. So, while the evidence for powerful eﬀects of
normalization of circulating levels of testosterone on glucose
homeostasis so far is limited, there are studies to prove that
administration of testosterone may have favorable eﬀects
on glycaemic control and the metabolic sequels of diabetes
mellitus.
10. New Perspectiveson Testosterone
In recent times, the understanding and thinking about the
(patho)physiological functions of testosterone have under-
gone a revolutionary development. The traditional assump-
tion was that hypogonadism in men usually resulted in loss
of libido and potency which could be restored by androgen
administration. While the signiﬁcance of testosterone for
male reproductive/sexual functioning has been obvious to
most physicians, they now need to familiarize themselves
with the insight that testosterone is a key player in glucose
homeostasis and lipid metabolism.
Physicians will have to make a change of their mindset
that testosterone, rather being a dangerous companion to
a man’s life, bringing joy but exacting its toll, is a vital
hormone for men’s health, from early prenatal development
to the end of a man’s life. Earlier it has been questioned
whether testosterone has an essential role to play in male
physiology. Recent epidemiological studies have found that
low testosterone levels are a predictor of mortality in elderly
men [90–94]. Obviously, epidemiological studies cannot
unravel cause relationships, but the evidence is convincing
that the decline in testosterone levels with aging is accounted
for rather by (age-related) disease than the calendar age of
men [95, 96]. Intervention studies provide potential answers
to the causality of the relationship. It is no exaggeration to
say that in modern medicine and endocrinology testosterone
is no longer a marginal hormone. Neither is it a life-
style hormone for those men seeking eternal youth. Its
deﬁciency leads to a serious deterioration of the health of
men expressing itself in the metabolic syndrome and its
sequels: diabetes mellitus type 2 and atherosclerotic disease,
osteoporosis and sarcopenia, all strongly limiting physical
independence in old age and accelerating morbidity and
mortality.
11. MeasuringSerum Testosterone
There is no generally accepted cutoﬀ value of plasma
testosterone for deﬁning androgen deﬁciency, and in the
absence of convincing evidence for an altered androgen
requirement in elderly men, Arbitrarily, the normal range of
testosterone and free testosterone (fT) levels in young males
is considered also valid for elderly men. Then the normal
levels of total testosterone are between 12 and 35nmol/L.
It is of note that the determination of reference values
of laboratory parameters is based on statistical analysis of
a population of subjects [97]. For the clinician workable
criteria are the following: the lower limit of normal of total
testosteroneis12nmol/LandoffT250pmol/L.Mostauthors
agree that plasma testosterone levels should be measured in
early morning samples in view of the circadian rhythm of
plasma testosterone, with shows its lowest values in the late
afternoon. (Late) afternoon samples might present unduly
low values and not be representative of a man’s androgen
status [58, 98]. The recommendation also agrees that a single
measurement providing a low testosterone value is to be
repeated, certain when that value would be enough reason
to start testosterone administration. Small ailments, like a
cold or other minor stressors, may temporarily suppress
circulating testosterone.
It will not be rare to ﬁnd rather ambiguous, border-
line normal/abnormal levels of plasma total testosterone
in elderly men, even in those men with clinical symp-
toms of androgen deﬁciency. In these cases, assessment
of bioavailable or free testosterone might be an asset.
Bioavailable testosterone can be measured in the laboratory
using the ammoniumsulphate precipitation technique. The
gold standard for free testosterone measurement still is
the dialysis method, although a mass spectrometry-based
assessment of free testosterone in ultraﬁltrates was recently
proposed as a candidate reference method (for review: [58]).
However, both ammoniumsulphate precipitation and the
dialysis technique are nonautomated, time-consuming, and
expensive techniques and therefore not routinely available
in the vast majority of laboratories. There has been a direct
radioimmunoassay claiming to measurefreetestosteronebut
this assay has been universally criticized because of lack of
accuracy and should not be used [58]
The two most widely used equations for calculating
bioavailable or free testosterone are those described by
Vermeulen et al. [99] and Sodergard et al. [100]. The
equations are largely identical apart from the association
constants for the binding of testosterone to albumin and sex
hormone-binding globulin.
At least two algorithms have been placed on the inter-
net as so-called bioavailable testosterone calculators
(http://www.issam.ch/ and http://www.get-back-on-track
.com/en/tools/kalkulator.php and http://www.him-link/
.com/) making these algorithms readily available for distant
users. It is redundant to measure/calculate biovailable/free
testosterone if plasma total testosterone appeared to be in
the truly hypogonadal (<6nmol/L)or in the truly eugonadal
range (>15nmol/L).
12. Safety Concerns
Traditionally, the majority of physicians associate the admin-
istration of testosterone, particularly to elderly men, with
a serious risk of inducing malignancies of the prostate or
exacerbating voiding problems of the elderly male.
Several follow-up studies of men receiving testosterone
treatment [101–103] have failed to demonstrate an exac-
erbation of voiding symptoms due to benign prostatic6 Journal of Obesity
hyperplasia. Complications such as urinary retention in
therapy groups did not occur at higher rates than in controls
receiving placebo.
The occurrence of prostate cancer after testosterone
administration to (elderly) men has been reported [104–
108] but its causality has not been established. Aging,
typically, increases the risk of developing prostate cancer.
By contrast, a variety of studies, using various designs
and testosterone formulations, over periods ranging from
several months to 15 years, in men with a wide range
of ages, have not revealed an increased risk of prostate
cancer [109–116]s e ef o rr e v i e w[ 117, 118]. A meta-analysis
found that testosterone treatment in older men compared
to placebo was not associated with a signiﬁcantly higher
risk of detection of prostate cancer, although the frequency
of prostate biopsies was much higher in the testosterone-
treated group than in the placebo group [103]. Presently, it is
believed that testosterone can be administered to men whose
prostate cancer has been radically cured [119].
The above applies also to the assessment of safety of
testosterone administration to elderly men. There is no
convincing evidence that testosterone is a main factor in
the development of prostate cancer in elderly men [120],
and guidelines for monitoring have been developed which,
if rigorously applied, render testosterone administration to
elderly men, an acceptably safe therapy in men without
a prior history of prostate carcinoma or without evidence
of harboring a prostate carcinoma [121, 122]. There are
now at least three publications demonstrating a lack of
prostate carcinoma recurrence with testosterone therapy
after deﬁnitive prostate carcinoma treatment. Two articles
h a v er e p o r t e dn oP S Ar e c u r r e n c ei nat o t a lo f1 7m e n ,
following radical prostatectomy in men with undetectable
PSA [123, 124]. A third study reported that no cancer
recurrence was noted in 31 hypogonadal men treated with
brachytherapy with a follow-up of approximately 5 years
[125]. These small studies suggest that normalization of
testosterone in men who have shown no signs of recurrence
of prostate cancer after treatment, testosterone replacement
could be beneﬁcial.
There is a consensus now that administration of testos-
terone to elderly men is a responsible practice provided
certain guidelines of professional bodies are followed with
regard to testosterone administration to elderly men [121,
126].
13. Conclusion
In recent times, the understanding and thinking about the
(patho)physiological functions of testosterone have under-
gone a revolutionary development. While the signiﬁcance
of testosterone for male reproductive/sexual functioning
has always been obvious to physicians, they now need to
familiarize themselves with the insight that testosterone is
a key player in glucose homeostasis, lipid metabolism, and
cardiovascular pathology. Physicians will have to change
theirmind-setandacceptthattestosteroneisavitalhormone
for many aspects of men’s health. The long-held belief that
testosterone has adverse eﬀects on cardiovascular disease
explaining the male preponderance in cardiovascular mor-
bidity and mortality appears not to be supported by rigorous
scientiﬁc testing. Recent epidemiological studies have found
that low testosterone levels are a predictor of mortality in
elderly men [90–92, 94].
Obviously, epidemiological studies cannot unravel cause
relationships. Intervention studies provide potential answers
to the causality of the relationship. It is no exaggeration to
say that in modern medicine and endocrinology testosterone
is no longer a marginal hormone. Neither is it a life-
style hormone for those men seeking eternal youth. Its
deﬁciency leads to a serious deterioration of the health of
men expressing itself in the metabolic syndrome and its
sequels: diabetes mellitus type 2 and atherosclerotic disease
accelerating morbidity and mortality. Intervention studies
in men with diabetes mellitus are limited in number but
hold promise. Normalization of testosterone levels may
improve insulin sensitivity and have favorable eﬀects on
visceraladiposityandlipidproﬁles.Thefearthattestosterone
administration to elderly men increases the risk of prostate
malignancies is not justiﬁed. It only requires prudence in
clinical management.
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